Trial Profile
A Phase 1/2a, Multi-Center, Dose Escalation/Dose Expansion, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs JAB-3068 (Primary)
- Indications Head and neck cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jacobio Pharmaceuticals
- 11 Mar 2022 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.
- 11 Mar 2022 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2022.
- 05 Aug 2020 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.